Bipolar Enucleation of the Prostate Versus Bipolar TURP (TURP)

July 17, 2026 updated by: Amgad Abdel Aziz, Ain Shams University

A Comparative Study Of Clinical Outcomes Of Bipolar Enucleation Of The Prostate Versus Bipolar TURP In Management Of Benign Prostatic Hyperplasia : A Randomized Controlled Clinical Trial

Bipolar enucleation of the prostate (BEEP) was introduced to treat patients with large prostate. The study compared the functional outcomes and perioperative complications of bipolar TURP and bipolar enucleation of large prostates above 80 gm.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Recent literature suggests that enucleation techniques may provide superior functional results, reduced bleeding, and lower retreatment rates. Nevertheless, there remains limited high-quality randomized controlled data directly comparing bipolar TURP and bipolar enucleation of prostate as a head to head comparison regarding functional outcomes and peri-operative complications.

In this study, a randomized controlled trial was performed to compare bipolar enucleation of the prostate versus bipolar transurethral resection of the prostate in BPH regarding symptoms relief, residual adenoma, urine flow rate and post-operative morbidity.

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Cairo Governorate
      • Cairo, Cairo Governorate, Egypt, 11566
        • Ain Shams University Hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • All male patients above the age of 40 years who presented to the urology clinic in Ain Shams university hospitals with BPH with prostate size 80 - 120 g and have any of the following criteria:
  • Voiding symptoms that are poorly responsive to medical treatment (IPSS more than 18 and Qmax less than 15 ml/sec)
  • Persistent or recurrent attacks of urine retention due to BPH.
  • Large bladder stones from BPH.
  • Recurrent UTI due to BPH.
  • Severe gross hematuria from BPH.

Exclusion Criteria:

  • Patients with untreated or active UTI.
  • Previous pelvic radiation or pelvicl trauma.
  • Patients with anesthesia contraindications such as uncontrolled diabetes mellitus, severe coagulation disorders and severe cardiac diseases.
  • Known or suspected neurogenic bladder.
  • Urethral stricture or urethral cancer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: bipolar TURP
transurethral resection of the prostate by bipolar current
Procedure: bTURP
transurethral resection of the prostate by bipolar current
Other Names:
  • TURIS
Active Comparator: BEEP
endoscopic enucleation of the prostate by bipolar current
Procedure: BEEP
endoscopic enucleation of the prostate by bipolar current
Other Names:
  • TUEP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
volume of residual prostatic adenoma
Time Frame: one month postoperative
measurement of volume of residual prostatic adenoma post bipolar TURP and BEEP was done by pelvi-abdominal ultrasound
one month postoperative
change in international prostate symptoms score
Time Frame: pre-operative, one, three, six and twelve months postoperative

The international prostate symptoms score is a patient-completed questionnaire for standardized assessment of lower urinary tract symptoms (LUTS). It includes seven questions that evaluate the following urinary symptoms:

  • Weak urinary stream (0 : 5)
  • Incomplete bladder emptying (0 : 5)
  • Straining during urination (0 : 5)
  • Intermittent urine flow (0 : 5)
  • Increased urinary frequency (0 : 5)
  • Urgency (0 : 5)
  • Nocturia (0 : 5) Grade 1 (score = 0 - 7) : Mild LUTS Grade 2 (score = 8 - 19) : Moderate LUTS Grade 3 (score = 20 - 35) : Severe LUTS
pre-operative, one, three, six and twelve months postoperative
improvement in maximum urine flow rate(Q max)
Time Frame: pre-operative, 1, 3, 6 and 12 months postoperative
Maximum urine flow rate was evaluated by Uroflowmetry
pre-operative, 1, 3, 6 and 12 months postoperative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
reduction in post voiding residual urine
Time Frame: pre-operative, 1, 3, 6 and 12 months postoperative
post voiding residual urine in bladder was evaluated by Trans-abdominal ultrasound
pre-operative, 1, 3, 6 and 12 months postoperative
operation time
Time Frame: during operation
Operation time was calculated from insertion of the cystoscope/resectoscope into the urethra to final removal of the scope
during operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ain Shams University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2025

Primary Completion (Actual)

June 30, 2026

Study Completion (Actual)

July 14, 2026

Study Registration Dates

First Submitted

July 17, 2026

First Submitted That Met QC Criteria

July 17, 2026

First Posted (Actual)

July 21, 2026

Study Record Updates

Last Update Posted (Actual)

July 21, 2026

Last Update Submitted That Met QC Criteria

July 17, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FMASU MS 56/2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Benign Prostate Hypertrophy(BPH)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe